journal article·2022-07Open access

Nanofiber capsules for minimally invasive sampling of biological specimens from gastrointestinal tract

Johnson V. John, Alec McCarthy, Yajuan Su, Daniel N. Ackerman, S.M. Shatil Shahriar, Mark A. Carlson, St. Patrick Reid, Joshua L. Santarpia, Wuqiang Zhu, Jingwei Xie

Acta Biomaterialia· Volume 146

Abstract

Accurate and rapid point-of-care tissue and microbiome sampling is critical for early detection of cancers and infectious diseases and often result in effective early intervention and prevention of disease spread. In particular, the low prevalence of Barrett's and gastric premalignancy in the Western world makes population-based endoscopic screening unfeasible and cost-ineffective. Herein, we report a method that may be useful for prescreening the general population in a minimally invasive way using a swallowable, re-expandable, ultra-absorbable, and retrievable nanofiber cuboid and sphere produced by electrospinning, gas-foaming, coating, and crosslinking. The water absorption capacity of the cuboid- and sphere-shaped nanofiber objects is shown ∼6000% and ∼2000% of their dry mass. In contrast, unexpanded semicircular and square nanofiber membranes showed <500% of their dry mass. Moreover, the swallowable sphere and cuboid were able to collect and release more bacteria, viruses, and cells/tissues from solutions as compared with unexpanded scaffolds. In addition to that, an expanded sphere shows higher cell collection capacity from the esophagus inner wall as compared with the unexpanded nanofiber membrane. Taken together, the nanofiber capsules developed in this study could provide a minimally invasive method of collecting biological samples from the duodenal, gastric, esophagus, and oropharyngeal sites, potentially leading to timely and accurate diagnosis of many diseases. STATEMENT OF SIGNIFICANCE: Recently, minimally invasive technologies have gained much attention in tissue engineering and disease diagnosis. In this study, we engineered a swallowable and retrievable electrospun nanofiber capsule serving as collection device to collect specimens from internal organs in a minimally invasive manner. The sample collection device could be an alternative endoscopy to collect the samples from internal organs like jejunum, stomach, esophagus, and oropharynx without any sedation. The newly engineered nanofiber capsule could be used to collect, bacteria, virus, fluids, and cells from the abovementioned internal organs. In addition, the biocompatible and biodegradable nanofiber capsule on a string could exhibit a great sample collection capacity for the primary screening of Barret Esophagus, acid reflux, SARS-COVID-19, Helicobacter pylori, and gastric cancer.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Electrospun Nanofibers in Biomedical Applications · Tissue Engineering and Regenerative Medicine · Tracheal and airway disorders

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (38)

Show source-provided references
1. Liquid biopsy: still early days for early detection10.1016/S0140-6736(18)31476-4 ↗
2. The case for early detection10.1038/nrc1041 ↗
3. Early detection of covid-19 through a citywide pandemic surveillance platform10.1056/NEJMc2008646 ↗
4. Planning against biological terrorism: lessons from outbreak investigations10.3201/eid0905.020388 ↗
5. Screening and surveillance for Barrett esophagus10.1001/jamainternmed.2014.6983 ↗
6. Screening for Barrett's esophagus
7. Cytosponge-trefoil factor 3 versus usual care to identify barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial10.1016/S0140-6736(20)31099-0 ↗
8. Barrett’s esophagus trial 3 (BEST3): study protocol for a randomised controlled trial comparing the cytosponge-TFF3 test with usual care to facilitate the diagnosis of oesophageal pre-cancer in primary care patients with chronic acid reflux10.1186/s12885-018-4664-3 ↗
9. Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett's esophagus10.1053/j.gastro.2012.09.060 ↗
10. Screening for Barrett's esophagus10.1053/j.gastro.2015.02.012 ↗
11. Accuracy, safety, and tolerability of tissue collection by cytosponge vs endoscopy for evaluation of eosinophilic esophagitis10.1016/j.cgh.2014.06.026 ↗
12. Economic evaluation of cytosponge®-trefoil factor 3 for Barrett esophagus: a cost-utility analysis of randomised controlled trial data10.1016/j.eclinm.2021.100969 ↗
13. Safety and acceptability of esophageal cytosponge cell collection device in a pooled analysis of data from individual patients10.1016/j.cgh.2018.07.043 ↗
14. Combined EsophaCap cytology and MUC2 immunohistochemistry for screening of intestinal metaplasia, dysplasia and carcinoma10.2147/CEG.S186958 ↗
15. Methylation biomarker panel performance in EsophaCap cytology samples for diagnosing Barrett's esophagus: a prospective validation study10.1158/1078-0432.CCR-18-3696 ↗
16. Expanding two-dimensional electrospun nanofiber membranes in the third dimension by a modified gas-foaming technique10.1021/acsbiomaterials.5b00238 ↗
17. Fast transformation of 2D nanofiber membranes into pre-molded 3D scaffolds with biomimetic and oriented porous structure for biomedical applications10.1063/1.5144808 ↗
18. Three-dimensional objects consisting of hierarchically assembled nanofibers with controlled alignments for regenerative medicine10.1021/acs.nanolett.9b00217 ↗
19. Converting 2D nanofiber membranes to 3D hierarchical assemblies with structural and compositional gradients regulates cell behavior10.1002/adma.202003754 ↗
20. Ultra-absorptive nanofiber swabs for improved collection and test sensitivity of SARS-CoV-2 and other biological specimens10.1021/acs.nanolett.0c04956 ↗
21. Three-dimensional printed PCL-based implantable prototypes of medical devices for controlled drug delivery10.1016/j.xphs.2015.12.012 ↗
22. Fabrication of injectable and superelastic nanofiber rectangle matrices (“peanuts”) and their potential applications in hemostasis10.1016/j.biomaterials.2018.06.031 ↗
23. Diagnosis of helicobacter pylori: what should be the gold standard10.3748/wjg.v20.i36.12847 ↗
24. Diagnosis of helicobacter pylori infection in a routine testing workflow: effect of bacterial load and virulence factors10.3390/jcm10132755 ↗
25. Clinical samples for SARS-CoV-2 detection: review of the early literature10.1016/j.clinmicnews.2020.07.001 ↗
26. At-home self-collection of saliva, oropharyngeal swabs and dried blood spots for SARS-CoV-2 diagnosis and serology: post-collection acceptability of specimen collection process and patient confidence in specimens
27. Gastrointestinal infection could be new focus for coronavirus diagnosis
28. Use of entero-test, a simple approach for non-invasive clinical evaluation of the biliary disposition of drugs10.1111/j.1365-2125.2011.03956.x ↗
29. Use of a non-invasive test (entero-test) in the detection of helicobacter pylori in children in an endemic area in colombia10.1097/MPG.0b013e318293e1e1 ↗
30. New forms of electrospun nanofiber materials for biomedical applications10.1039/D0TB00271B ↗
31. Electrospun nanofibers: new concepts, materials, and applications10.1021/acs.accounts.7b00218 ↗
32. Electrospinning and electrospun nanofibers: methods, materials, and applications10.1021/acs.chemrev.8b00593 ↗
33. Recent advances in the detection and management of early gastric cancer and its precursors10.1136/flgastro-2018-101089 ↗
34. Esophageal cancer: a review of epidemiology, pathogenesis, staging workup and treatment modalities10.4251/wjgo.v6.i5.112 ↗
35. Barrett's esophagus: a review of diagnostic criteria, clinical surveillance practices and new developments
36. Zollinger-Ellison syndrome: classical considerations and current controversies10.1634/theoncologist.2013-0369 ↗
37. Gastric cancer detection using gastric juice pepsinogen and melanoma-associated gene RNA10.1309/AJCPOHXRM5IYXVOC ↗
38. Detection of mycobacterium tuberculosis in gastric aspirates collected from children: hospitalization is not necessary10.1542/peds.102.4.e40 ↗